## Supplementary Checklist: STrengthening the REporting of Genetic Association studies (STREGA) reporting recommendations, extended from STROBE Statement

Item	Item no	STROBE Guideline	Extension for Genetic Association Studies (STREGA)	Section, paragraph
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract.		Abstract: lines 38-39
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found.		Abstract: lines 38-45
Introduction				
Background rationale	2	Explain the scientific background and rationale for the investigation being reported.		Lines 48-57
Objectives	3	State specific objectives, including any prespecified hypotheses	State if the study is the first report of a genetic association, a replication effort, or both.	Lines 37-39, 59-60
Methods				
Study design	4	Present key elements of study design early in the paper.		Lines 60-66
Setting	5	Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow-up and data collection.		Methods: Study populations
Participants	6	<ul> <li>(a) Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.</li> <li>Case-control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls.</li> </ul>	Give information on the criteria and methods for selection of subsets of participants from a larger study, when relevant.	Methods: Study populations Genotyping, imputation, and quality control
		Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants.  (b) Cohort study – For matched studies, give matching criteria and number of exposed and unexposed.  Case-control study – For matched studies,		
		give matching criteria and the number of controls per case.		

Variables	7	(a) Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	(b) Clearly define genetic exposures (genetic variants) using a widely – used nomenclature system. Identify variables likely to be associated with population stratification (confounding by ethnic origin).	Methods: Genotyping, imputation, and quality control; Meta-analyses; Characterization of association signals; Mendelian randomization
Data sources measurement	8*	(a) For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.	(b) Describe laboratory methods, including source and storage of DNA, genotyping methods and platforms (including the allele calling algorithm used, and its version), error rates and call rates. State the laboratory /centre where genotyping was done. Describe comparability of laboratory methods if there is more than one group. Specify whether genotypes were assigned using all of the data from the study simultaneously or in smaller batches.	Methods: Genotyping, imputation, and quality control
Bias	9	(a) Describe any efforts to address potential sources of bias.	(b) For quantitative outcome variables, specify if any investigation of potential bias resulting from pharmacotherapy was undertaken. If relevant, describe the nature and magnitude of the potential bias, and explain what approach was used to deal with this.	NA
Study size	10	Explain how the study size was arrived at.		Methods: Study populations; Genotyping, imputation, and quality control

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why.	If applicable, describe how effects of treatment were dealt with.	NA
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding.	State software version used and options (or settings) chosen.	Methods: Genotyping, imputation, and quality control; GWAS; Meta- analyses; Characterization of association signals; SNP- based heritability and genetic correlations; Mendelian randomization
		(b) Describe any methods used to examine subgroups and interactions.		NA
		(c) Explain how missing data were addressed.		Methods: Genotyping, imputation, and quality control
		(d) <b>Cohort study</b> – If applicable, explain how loss to follow-up was addressed.		Methods: Study populations
		Case–control study – If applicable, explain how matching of cases and controls was addressed.		
		Cross-sectional study – If applicable, describe analytical methods taking account of sampling strategy.		
		(e) Describe any sensitivity analyses.	(f) State whether Hardy- Weinberg equilibrium was considered and, if so, how.	NA Methods: Genotyping, imputation, and quality control
			(g) Describe any methods used for inferring genotypes or haplotypes.	Methods: Genotyping, imputation, and quality control
			(h) Describe any methods used to assess or address population stratification.	Methods: GWAS

			(i) Describe any methods used to address multiple comparisons or to control risk of false positive findings.	Methods: Meta-analyses
			(j) Describe any methods used to address and correct for relatedness among subjects.	Methods: Genotyping, imputation, and quality control
Results	12*	(a) Papart the numbers of individuals at each	Poport numbers of	1
Participants	13*	(a) Report the numbers of individuals at each stage of the study – e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up and analysed.	Report numbers of individuals in whom genotyping was attempted and numbers of individuals in whom genotyping was successful.	NA (Numbers of individuals in whom genotyping was attempted is not available for large biobank
		(b) Give reasons for non-participation at each stage.		data)
		(c) Consider use of a flow diagram.		
Descriptive data	14*	<ul> <li>(a) Give characteristics of study participants</li> <li>(e.g. demographic, clinical, social) and information on exposures and potential confounders.</li> </ul>	Consider giving information by genotype.	Methods: Study populations; Genotyping, imputation, and
		(b) Indicate the number of participants with missing data for each variable of interest.		quality control
		(c) <b>Cohort study –</b> Summarize follow-up time, e.g. average and total amount.		
Outcome data	15*	Cohort study – Report numbers of outcome events or summary measures over time.	Report outcomes (phenotypes) for each genotype category over time	Lines 61-64
		Case–control study – Report numbers in each exposure category, or summary measures of exposure.	Report numbers in each genotype category	
		Cross-sectional study – Report numbers of outcome events or summary measures.	Report outcomes (phenotypes) for each genotype category	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence intervals). Make clear which confounders were adjusted for and why they were included.  (b) Report category boundaries when		Table 1; Tables S1 and S2
		continuous variables were categorized.  (c) If relevant, consider translating estimates of relative risk into absolute risk for a		
		meaningful time period.	(d) Report results of any adjustments for multiple comparisons.	Only results significant after multiple comparisons are reported.

Other analyses	17	(a) Report other analyses done – e.g. analyses of subgroups and interactions, and sensitivity analyses.		N A
			(b) If numerous genetic exposures (genetic variants) were examined, summarize results from all analyses undertaken.	Table 1, Figure 1
			(c) If detailed results are available elsewhere, state how they can be accessed.	Title page: lines 33-34
Discussion				
Key results	18	Summarize key results with reference to study objectives.		Lines 171-173
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.		Lines 147-149
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.		Lines 158-159, 171-173
Generalizability	21	Discuss the generalizability (external validity) of the study results.		Lines 167-169, 174-175
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.		Acknowledgeme nts and funding

STROBE: STtrengthening the Reporting of Observational Studies in Epidemiology

<sup>\*</sup>Give information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.